Access MeMed BV®
Accurately aids in distinguishing between bacterial and viral infections
Receive your quote directly from the manufacturer.
Since bacterial and viral infections are clinically indistinguishable, physicians are often challenged to decide whether to treat or not with antibiotics.
By providing host response information, we help physicians make more informed decisions about how and when to treat.
Using serum or plasma, Access MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a likely viral immune response with an overall diagnostic accuracy of 95% and a negative predictive value for bacterial infections of 98.8%.
The Access MeMed BV assay is now available on Beckman Coulter’s DxI 9000 and Access 2 immunoassay analyzers allowing you to leverage your existing lab infrastructure to empower timely, evidence-based decision making.
Brochures
Host response assay to distinguish bacterial and viral infections
This brochure introduces MeMed BV®, a host response assay designed to differentiate between bacterial and viral infections using a simple blood test. The assay integrates three immune protein biomarkers into a computational score, enabling clinicians to make more informed treatment decisions and reduce inappropriate antibiotic use. Validated across more than 20,000 patients, the test demonstrates high diagnostic accuracy and supports timely clinical decision-making. Available on Beckman Coulter immunoassay platforms, MeMed BV delivers rapid results within routine laboratory workflows, helping address key challenges in infectious disease diagnosis and antibiotic stewardship.
Clinical evidence supporting host response testing for infection diagnosis
This clinical evidence overview summarizes multiple studies evaluating the performance and clinical utility of MeMed BV, a host response assay designed to distinguish between bacterial and viral infections. Across more than 20,000 patients and multiple international studies, the assay consistently demonstrates high diagnostic accuracy, outperforming traditional biomarkers such as CRP and procalcitonin. Clinical trials and real‑world studies show that MeMed BV can reduce unnecessary antibiotic use, support decision-making in emergency and urgent care settings, and improve patient management without increasing adverse outcomes. These findings highlight the potential of host response diagnostics to address diagnostic uncertainty and improve antibiotic stewardship.
From emerging threats to diagnostic breakthroughs: A strategic look ahead in AMR
Wednesday, May 27 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Don’t miss this chance to learn from industry professionals in a dynamic session filmed at ESCMID Global 2026 followed by a live Q&A session. Brought to you by Danaher companies, Beckman Coulter Diagnostics and Cepheid, this session will explore the role of emerging diagnostic modalities to combat the development and spread of antimicrobial resistance (AMR).
The session will apply lessons learned from MRSA and VRE testing to emerging AMR threats such as CRE and C. auris. There will be an exploration of AMR gene detection using molecular methods such as syndromic PCR panels and NGS. Besides molecular methods, we will explore emerging rapid phenotypic antimicrobial susceptibility tests (AST) and bacterial versus viral host response-based diagnostics and their potential to improve antimicrobial stewardship and patient outcomes.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 90 minutes
- Format: Rebroadcast of recorded symposium from ESCMID Global 2026 with live Q&A
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Improving acute infection diagnosis using host- and pathogen-focused approaches – A rebroadcast from SAEM26 with live Q&A
Tuesday, June 16 at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
This SelectScience® webinar features a rebroadcast from the Society for Academic Emergency Medicine 2026 Annual Meeting (SAEM26), followed by a live Q&A session.
Diagnostic uncertainty in acute infections remains a core challenge in emergency medicine. Brought to you by Danaher companies, Beckman Coulter Diagnostics and Cepheid, this webinar examines two complementary diagnostic strategies to help close this gap: pathogen-based testing and host response biomarkers.
The first session will review evidence-based approaches to pharyngitis including clinical scoring systems and diagnostic strategies for Group A Strep detection such as PCR. The second session introduces new host-response tests to differentiate bacterial from viral infection.
Through case-driven discussions, participants will explore practical workflows, stewardship alignment, and clinical impact including time-to-diagnosis, antibiotic optimization, clinical outcomes, and patient disposition.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Format: Rebroadcast of recorded symposium from SAEM26 with live Q&A
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
CE-marked Access MeMed BV brings rapid bacterial vs viral answers to the core lab
At ESCMID Global 2026, leaders from Danaher and Beckman Coulter Diagnostics unveiled a major milestone: the CE-marked European launch of the Access MeMed BV® host response assay, bringing rapid bacterial vs viral differentiation to familiar core laboratory immunoassay platforms.
In this interview, Ephraim Tsalik (Chief Scientific Officer, Infectious Disease & Acute Care, Danaher) and Dr. Stephanie Mitchell (Senior Director, Infectious Diseases & Microbiology, Beckman Coulter Diagnostics) explain how host-response testing can integrate seamlessly into routine workflows on DxI 9000 and Access 2, delivering actionable results in around 20 minutes to support earlier, more confident clinical decisions.
You will also hear how the test was developed using omics and machine learning, and distilled into three biomarkers that generate a clear, interpretable score, helping clinicians address one of the most persistent challenges in medicine, and strengthen antimicrobial stewardship and diagnostic pathways.
Interview recorded at ESCMID Global 2026.
Product Overview
Links
Featured products
Request Quote for All Products
Scopio Labs X100 & X100HT Digital Morphology Solution
Beckman Coulter DiagnosticsFull-Field Digital Cell Morphology
